Proliferative Diabetic Retinopathy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Proliferative Diabetic Retinopathy Market Trends and Insights

Rising Prevalence of Diabetes and Longer Life Expectancy

Global diabetes prevalence doubled between 1990 and 2022, rising from 7% to 14% of the adult population. Longer lifespans mean patients live with the disease for decades, and epidemiologic studies show a 4.36-fold higher retinopathy risk after 10 years of diabetes ^{[1]Soroush Seifi, “Real-World Outcomes of Anti-VEGF Biosimilars,” nature.com}. The International Diabetes Federation projects 783.2 million cases by 2045, with middle-income economies facing the largest increases. Germany illustrates this path; analysts expect type 2 diabetes prevalence to reach 14.2 million by 2040. As prevalence climbs, the proliferative diabetic retinopathy market gains a stable patient base for both pharmacologic and surgical care.

Increasing Adoption of Intravitreal Anti-VEGF Biologics

Medicare claims show aflibercept injections rose 138% between 2014 and 2023, reflecting clinician confidence in anti-VEGF therapy. In May 2025 the FDA cleared Genentech’s Susvimo for diabetic retinopathy, enabling continuous delivery with biannual refills. Regional access remains uneven: physician density drives large differences in injection rates across U.S. states, while biosimilars such as Yesafili and Opuviz began easing price barriers in 2025. Comparable efficacy data from Iran’s ATRIA trial further validate the biosimilar pathway. Wider biologic uptake elevates the proliferative diabetic retinopathy market by expanding the treated population and encouraging longer therapy duration.

Availability of Minimally Invasive Retinal Laser & Vitrectomy Platforms

Subthreshold micropulse laser therapy treats pathology without visible retinal scarring, helping preserve vision while reducing adverse events ^{[2]José-Luis Montero, “Micropulse Laser Therapy Review,” mdpi.com}. Robotic systems developed at the University of Utah achieve sub-micrometer precision, supporting delicate sub-retinal procedures under local anesthesia. Hypersonic vitrectomy devices such as Vitesse reach cut rates equal to millions of cuts per minute, although early trials reported technical challenges in 46% of cases. As technology matures, surgeons can combine 23-gauge vitrectomy with cataract extraction for faster recovery. These advances improve outcomes and shorten operating times, reinforcing patient and payor adoption of surgical care.

Growing Healthcare Expenditure Boosting Access to Eye-Care Services

Emerging markets allocate larger budgets to diabetes care as incomes rise; Eastern Mediterranean countries record per-patient costs ranging from USD 1,707 in Iran to USD 555 in Pakistan. Brazil’s primary-care network reports only 44.8% of adults achieving glycemic control, reinforcing demand for specialist ophthalmic services. Reimbursed tele-ophthalmology programs in Latin America and Asia-Pacific offer cost-effective screening at scale. Higher health spending widens therapeutic reach and raises the ceiling for the proliferative diabetic retinopathy market.

AI-Enabled Screening Programs Enabling Earlier Detection

Real-world deployments of autonomous image-analysis software achieve 87.7% sensitivity and 90.6% specificity for vision-threatening retinopathy. U.S. primary-care clinics using these tools improved screening rates by 31 percentage points in 2024. Asia-Pacific pilots replicate this success; India’s SMART DROP protocol combines AI triage with community outreach, creating a template for low-cost coverage. Earlier detection shifts more patients into timely intervention and underpins revenue growth across therapeutic categories within the proliferative diabetic retinopathy market.

Long-Acting Ocular Implants Reducing Treatment Burden

Genentech’s Susvimo delivers ranibizumab for six months, cutting annual injection frequency by 83% compared with monthly therapy. Ocular Therapeutix’s axitinib insert and Kodiak Sciences’ tarcocimab sustained-delivery platform follow the same path, targeting ≥ 6-month dosing intervals. Lower visit frequency improves adherence, limits chair time, and may reduce indirect costs to patients and payors. The cumulative impact adds steady tailwinds to the proliferative diabetic retinopathy market.

Extended Regulatory Approval Timelines for Ophthalmic Biologics

New entrants face multiyear data requirements for biologic comparability, toxicology, and device-drug combinations. Regeneron’s Eylea HD secured priority review in April 2025 yet still waits for an August action date. Oculis needed more than three years to complete Phase 3 enrollment for a topical steroid therapy. Gene and cell therapies demand bespoke manufacturing audits that lengthen review cycles. Smaller firms often cede ground to incumbents that can finance lengthy development and navigate diverse regional rules, tempering overall market growth.

High Cost of Anti-VEGF Injections Limiting Adherence

U.S. payers impose step-therapy rules on up to 75% of commercial policies, pushing patients toward lower-cost off-label bevacizumab before accessing approved agents. Vision loss nonetheless generated USD 134.2 billion in secondary costs in 2024, dwarfing drug spending and illustrating the cost-of-non-treatment paradox. Administrative delays further extend initiation times; retina practices report that prior authorization adds an average of nine days to first injection. Emerging markets face steeper barriers: per-patient diabetes spending across Middle East and North Africa economies varies by more than 300%, placing branded biologics beyond reach. Biosimilars may ease the burden, but uptake is slowed by limited physician familiarity and institutional contracting.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type – Anti-VEGF Lead Strengthens While Lasers Surge

In revenue terms, anti-VEGF biologics generated 66.78% of proliferative diabetic retinopathy market share in 2025, reflecting proven vision-saving efficacy. Laser surgery has become the fastest-advancing option, growing at 8.99% CAGR on the back of subthreshold micropulse platforms that avoid tissue damage. Corticosteroids remain relevant through implants such as Ozurdex that release medication over four to six months. Vitrectomy is adopting 23-gauge and 25-gauge tools, which shorten procedure time and recovery. Combination agents like faricimab target both VEGF-A and Ang-2, yielding superior durability in real-world studies.

Sustained-release implants position manufacturers for durable revenue streams. Genentech’s Susvimo expansion into diabetic retinopathy in 2025 underscores the trend, while gene therapy candidates such as ABBV-RGX-314 advance toward pivotal trials. Novel mechanisms, including plasma kallikrein inhibition, broaden the therapeutic playbook. Across modalities, a shift toward personalized regimens catering to disease severity and patient preferences widens addressable demand in the proliferative diabetic retinopathy market.

By Mode of Administration – Intravitreal Dominance Faces Non-invasive Rivals

Intravitreal injection retained 46.92% share of proliferative diabetic retinopathy market size in 2025 thanks to entrenched procedure workflows. Yet topical and periocular delivery grows at 9.22% CAGR, propelled by Phase 3 progress for eye-drop steroids and deep-penetration nanocarriers. Suprachoroidal platforms inject therapy between sclera and choroid, targeting the retina more directly while sparing vitreous manipulation. Sub-retinal gene therapy remains an option in select centers using precision robotics from academic innovators . As sustained-release reservoirs and biodegradable inserts mature, frequent office injections could shift to outpatient implant surgeries, realigning revenue mix within the proliferative diabetic retinopathy market.

Safety findings motivate investment in alternative routes. Reports of severe intraocular inflammation after high-dose aflibercept and faricimab underscore concerns. Continuous-delivery implants bypass repeated needle entries, while topical programs eliminate injection entirely. The race to replicate intravitreal efficacy through less invasive access will shape administration trends through 2031.

By End-User – Specialized Care Settings Accelerate

Hospitals carried 61.91% of proliferative diabetic retinopathy market size in 2025, but ophthalmology clinics are growing at 8.79% CAGR as payors favor lower-cost, high-throughput environments. A projected shortfall of 2,650 ophthalmologists in the United States by 2035 is encouraging multi-clinic chains to streamline specialist productivity. Ambulatory centers now handle an increasing share of vitrectomies, taking advantage of bundled payment incentives. Teleophthalmology and AI triage allow clinics to reach rural areas where only 29% of patients currently have adequate specialist access.

Consolidation continues: Cencora acquired Retina Consultants of America for USD 4.6 billion in January 2025, creating a nationwide retina super-group. Integrated hospital systems respond by establishing retina centers of excellence within tertiary facilities to retain procedure revenue. Hybrid models that mix large hospital infrastructure with clinic-level efficiency are likely to dominate end-user dynamics across the proliferative diabetic retinopathy market.

Geography Analysis

North America captured 42.85% proliferative diabetic retinopathy market share in 2025, supported by broad insurance coverage, fast regulatory cycles, and early adoption of sustained-release therapies. Yet workforce deficits present a strategic obstacle; a 12% decline in ophthalmologist supply against 24% growth in demand through 2035 has already triggered consolidation and tele-ophthalmology rollouts. AI-based screening initiatives now log sensitivities above 92%, reinforcing North America’s leadership in digital health integration.

Asia-Pacific is the fastest-growing region, expanding at a 10.15% CAGR as demographic shifts, urbanization, and rising incomes drive disease incidence and treatment access. Chinese studies indicate diabetic retinopathy prevalence between 24.7% and 43.1% among diagnosed diabetics. India’s SMART DROP protocol illustrates scalable public-health approaches that raise detection in rural districts. Japan and South Korea leverage established reimbursement systems to absorb premium implants and gene therapies, while Southeast Asia focuses on mobile screening units and subsidized biologic procurement. These layered strategies widen the addressable segment of the proliferative diabetic retinopathy market across diverse APAC economies.

Europe, the Middle East and Africa, and South America show varied trajectories. Germany may see diabetes cases climb to 14.2 million by 2040 because of post-pandemic incidence trends. Brazil’s Type 1 diabetes registry recorded a 35.7% retinopathy rate, showing room for expanded retina services. Tele-ophthalmology helps overcome geographic barriers across Pacific Island Countries and Territories, hinting at replication potential for other dispersed geographies.

Regulatory Landscape

Regulation for proliferative diabetic retinopathy (PDR) therapeutics covers biologics, drug-device combination products, and post-market safety oversight, with the FDA and EMA serving as the main global reference points. In the United States, the FDA approval of Genentech's Susvimo for diabetic retinopathy in May 2025 underscored the added review complexity for implantable continuous-delivery systems, while the FDA approval of Pavblu (aflibercept-ayyh) in August 2024 reinforced the biosimilar pathway for anti-VEGF competition in DR indications.

In Europe, biosimilar momentum is also visible in EMA actions, including the EU marketing authorization for Eyluxvi (aflibercept biosimilar) in 2025. Alongside product approvals, 2026 introduced procedural tightening around lifecycle management, including EMA updates to the variations framework and stability-testing guidance that apply from January 2026. This increases the practical value of well-prepared post-approval change packages for ophthalmic biologics and combination products. While AI screening tools sit outside this report's revenue scope, related device rules, for example Class II requirements for retinal diagnostic software under 21 CFR 886.1100, can shape clinical adoption pathways and influence referral volumes into PDR care.

Value Chain Analysis

The PDR value chain starts with discovery and clinical development of anti-VEGF biologics, sustained-release systems, steroids, and emerging gene-therapy approaches, followed by regulatory submission and scale-up in specialized sterile manufacturing for injectables and implantable delivery systems. Late-stage development and approvals increasingly hinge on platform capabilities and partner selection, illustrated by AbbVie and REGENXBIO advancing ABBV-RGX-314 toward Phase 3 plans for diabetic retinopathy, supported by an in-office suprachoroidal microinjector, and MSD initiating the Phase 2b/3 BRUNELLO trial (Restoret, MK-3000) in 2024, which broadens upstream R&D beyond traditional anti-VEGF-only programs.

Downstream, the chain moves through hospital pharmacies, specialty distributors, and retina clinics, where reimbursement, procurement contracts, and cold-chain handling influence utilization. Brand incumbents and biosimilar entrants compete for formulary placement and tenders as biosimilars expand choice in ranibizumab and aflibercept classes, while device-enabled care models gain share through implant procedures such as Susvimo, approved by the FDA in May 2025 for diabetic retinopathy. The last mile is delivered in high-throughput retina practices and ambulatory settings, where chair-time constraints, prior authorization, and specialist shortages can limit access, increasing the operational value of longer-durability therapies and standardized injection or implant workflows.

Market Opportunities and Future Outlook

A key whitespace in PDR care is reducing the cumulative burden of frequent intravitreal therapy while maintaining vision outcomes, which creates room for differentiated durability and delivery approaches. The FDA approval of Genentech's Susvimo for diabetic retinopathy in May 2025 gives a commercial reference point for continuous-delivery implants with infrequent refills, while the June 2026 first-patient-dosed milestone in REGENXBIO's Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (ABBV-RGX-314) in diabetic retinopathy highlights ongoing investment in one-time or infrequent-intervention modalities that can shift clinic throughput dynamics.

Access expansion is another opportunity track, particularly through lower-cost biologic options and simplified procurement in systems under cost pressure. The FDA approval of Amgen's Pavblu (aflibercept-ayyh) in August 2024, combined with subsequent EU biosimilar actions such as EMA authorization for Eyluxvi in 2025, supports broader competitive pricing and contracting levers for payers and providers, especially where step-therapy and prior authorization slow treatment initiation. Operationally, the ongoing shortage of retinal specialists increases demand for approaches that reduce visit frequency per treated patient, aligning with adoption of sustained-release implants, extended-interval anti-VEGF regimens, and care pathways that push stable follow-up into more efficient clinic schedules.